Objective: To determine the prevalence of non-motor symptoms (NMS) and their impact on quality of life (QoL) in Mexican individuals with Parkinson’s disease (PD), aiming to guide interventions for enhancing overall QoL in this population.

Background: NMS, especially cognitive impairments, play a crucial role in the QoL of people with neurological conditions like PD. Their impact extends beyond motor symptoms, significantly affecting daily activities and interpersonal relationships, making NMS a key focus for improving overall QoL in PD patients. This study aimed to highlight the prevalence of non-motor symptoms and their correlation with QoL in Mexican PD population.

Method: The ReMePark-2 is an observational, prospective, analytical study including Mexican people living with PD (PwP). Variables collected include gender, age, education years (y), comorbidities, PD evolution in y, Hoehn-Yahr Stage (HYS), levodopa dosage, MDS-UPDRS parts 1, 2, 3 and 4, NMSS, Montreal Cognitive Assessment (MoCA) and PDQ-8i were collected. QoL, using the PDQ-8i, was correlated with each of the MDS-NMSS subdomains. Statistical analysis was conducted using Python.

Results: 1038 Mexican PwP (56.6% males; 63.5±12.8 years old) were included. Mean PD evolution 6.6±5.5 years, 77.1% in HY stages 2-3, mean levodopa dose 696.4±382.1 mg/day. Spearman’s correlations were significant between QoL and MDS-UPDRS-II (r=0.70), MDS-UPDRS-I (r=0.63), MDS-NMSS mood (r=0.55), sleep-fatigue (r=0.44), gastrointestinal (r=0.43), MDS-UPDRS-III (r=0.39), MDS-NMSS attention (r=0.37), MDS-NMSS urinary (r=0.33).

Conclusion:

Acknowledging the significance of NMS is paramount in enhancing the overall well-being and daily functioning of patients. These aspects, often overlooked during medical consultations, play a pervasive role in the patient’s experience and should not be underestimated. By recognizing and addressing NMS, healthcare professionals can contribute significantly to a more comprehensive and effective approach to patient care, ultimately leading to improved outcomes and a better QoL for PwP.

References: Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease [published correction appears in Nat Rev Neurosci. 2017 Aug;18(8):509]. Nat Rev Neurosci. 2017;18(7):435-450. doi:10.1038/nrn.2017.62

Dissanayaka, N. N., Sellbach, A., Silburn, P. A., O’Sullivan, J. D., Marsh, R., & Mellick, G. D. (2011). Factors associated with depression in Parkinson’s disease. Journal of affective disorders, 132(1-2), 82–88. https://doi.org/10.1016/j.jad.2011.01.021

Kasten, M., Kertelge, L., Brüggemann, N., van der Vegt, J., Schmidt, A., Tadic, V., Buhmann, C., Steinlechner, S., Behrens, M. I., Ramirez, A., Binkofski, F., Siebner, H., Raspe, H., Hagenah, J., Lencer, R., & Klein, C. (2010). Nonmotor symptoms in genetic Parkinson disease. Archives of neurology, 67(6), 670–676. https://doi.org/10.1001/archneurol.67.6.670

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/prevalence-of-non-motor-symptoms-and-their-impact-in-quality-of-life-in-pd-a-mexican-registry-2011-2019-the-remepark-2-study/